sinc
decemb
coronaviru
diseas
caus
sever
acut
respiratori
syndrom
quickli
spread
across
world
approxim
case
would
develop
sever
ill
need
intervent
intens
care
unit
organ
dysfunct
includ
acut
respiratori
distress
syndrom
shock
acut
cardiac
injuri
acut
renal
injuri
could
occur
sever
case
lead
poor
clinic
outcom
follow
infect
high
viral
load
overexuber
host
immun
respons
involv
innat
acquir
immun
simultan
contribut
pathogenesi
organ
injuri
activ
host
immun
character
lymphopenia
cytokin
releas
storm
cr
dysfunct
immun
respons
virusspecif
antigen
increas
clinic
data
indic
neutrophiltolymphocyt
ratio
nlr
identifi
power
predict
prognost
indic
sever
howev
dynam
antibodi
upon
viru
infect
relat
diseas
statu
outcom
remain
determin
evalu
antibodi
respons
within
day
symptom
onset
laboratoryconfirm
case
one
compon
overal
exagger
immun
activ
sever
infect
develop
immun
phenotyp
base
late
igg
respons
nlr
could
help
determin
diseas
sever
clinic
outcom
patient
includ
patient
admit
renmin
hospit
wuhan
univers
januari
march
total
laboratoryconfirm
patient
includ
studi
confirm
diagnosi
defin
posit
result
use
realtim
reversetranscriptas
polymerasechainreact
rtpcr
detect
routin
nasal
pharyng
swab
specimen
antibodi
assay
serum
sampl
collect
admiss
convalescentphas
date
day
initi
symptom
onset
retrospect
evalu
antibodi
respons
clinic
diseas
sever
clinic
outcom
studi
receiv
approv
research
ethic
committe
renmin
hospit
wuhan
univers
wuhan
china
approv
number
research
ethic
committe
waiv
requir
inform
consent
studi
start
urgent
need
collect
epidemiolog
clinic
data
analyz
data
anonym
clinic
featur
includ
clinic
symptom
sign
laboratori
analys
treatment
outcom
obtain
hospit
electron
medic
record
accord
previous
design
standard
data
collect
form
date
symptom
onset
initi
diagnosi
death
record
accur
increas
accuraci
collect
data
two
research
independ
review
data
collect
form
also
directli
commun
patient
famili
member
ascertain
epidemiolog
symptom
data
antiigg
antiigm
antibodi
detect
use
human
igg
igm
chemiluminesc
analysi
clia
assay
panel
shenzhen
yhlo
biotech
co
ltd
shenzhen
china
highspe
clia
system
iflash
shenzhen
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
yhlo
biotech
co
ltd
shenzhen
china
proinflammatori
cytokin
includ
interleukin
il
tumor
necrosi
detect
use
human
cytokin
standard
assay
panel
et
healthcar
inc
shanghai
china
bioplex
system
biorad
hercul
ca
usa
accord
manufactur
instruct
nlr
calcul
divid
absolut
neutrophil
count
lymphocyt
count
descript
analys
use
determin
patient
epidemiolog
clinic
featur
continu
variabl
present
median
interquartil
rang
iqr
categor
variabl
express
percentag
differ
categori
mean
continu
variabl
compar
use
independ
group
test
data
normal
distribut
otherwis
mannwhitney
test
use
chisquar
test
fisher
exact
test
adopt
categori
variabl
statist
analys
studi
perform
use
stata
softwar
stata
corpor
colleg
station
tx
usa
twosid
p
valu
less
consid
statist
signific
total
patient
diagnosi
laboratoryconfirm
record
renmin
hospit
wuhan
univers
analyz
median
age
year
iqr
rang
year
patient
male
patient
sever
time
sampl
march
patient
die
total
patient
requir
supplement
oxygen
stage
ill
total
patient
administr
highdos
corticosteroid
number
patient
receiv
mechan
ventil
administr
intraven
immunoglobin
respect
patient
recov
infect
diseas
sever
patient
recov
antivir
support
therapi
patient
convalescentphas
sera
analysi
patient
detect
sera
detect
sera
shown
figur
igg
first
detect
day
ill
peak
level
occur
fourth
week
wherea
igm
first
detect
day
ill
peak
level
occur
second
week
median
igg
igm
level
convalescentphas
sera
within
day
includ
patient
compar
among
sever
nonsever
patient
higher
igm
level
detect
patient
sever
diseas
compar
nonsever
diseas
earli
stage
day
wherea
higher
igg
level
detect
late
stage
day
figur
use
median
cutoff
valu
stratifi
high
level
igm
igg
interestingli
sever
case
frequent
occur
patient
low
igm
level
auml
high
igm
level
auml
versu
figur
sever
case
frequent
found
patient
high
igg
level
auml
compar
low
igg
level
auml
versu
figur
consid
nlr
link
innat
immun
antiigg
respons
indic
acquir
immun
stratifi
patient
late
stage
four
differ
immun
respons
phenotyp
high
nlr
high
igg
level
nlr
hi
igg
hi
high
nlr
low
igg
level
nlr
hi
igg
lo
low
nlr
high
igg
level
nlr
lo
igg
hi
low
nlr
high
igg
level
nlr
lo
igg
lo
accord
nlr
cutoff
detect
igg
level
cutoff
auml
sever
rate
patient
nlr
hi
igg
hi
nlr
hi
igg
lo
nlr
lo
igg
hi
nlr
lo
igg
lo
phenotyp
respect
p
figur
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
next
ask
whether
proinflammatori
cytokin
level
cell
count
consist
immun
phenotyp
shown
tabl
sever
patient
higher
proinflammatori
cytokin
level
includ
nonsever
patient
especi
nlr
hi
igg
hi
nlr
hi
igg
lo
phenotyp
p
furthermor
sever
patient
nlr
hi
igg
hi
nlr
hi
igg
lo
phenotyp
higher
proinflammatori
cytokin
level
includ
decreas
cell
count
compar
nlr
lo
igg
lo
phenotyp
p
particular
igg
igm
higher
sever
patient
nlr
lo
igg
hi
phenotyp
nlr
lo
igg
lo
phenotyp
p
also
analyz
treatment
clinic
outcom
patient
differ
combin
immun
respons
phenotyp
dead
case
found
popul
nlr
hi
igg
hi
nlr
hi
igg
lo
phenotyp
figur
howev
sever
case
earli
stage
convalesc
sera
collect
allow
separ
analysi
antiigm
respons
studi
found
enhanc
igm
level
earli
stage
high
level
frequent
found
patient
sever
diseas
igg
level
increas
late
stage
wherea
high
level
igg
frequent
found
patient
sever
diseas
result
indic
besid
antivir
efficaci
antibodi
respons
might
associ
secondari
antibodymedi
organ
damag
use
nlr
igg
level
detect
sera
late
stage
develop
combin
immun
respons
phenotyp
could
predict
diseas
sever
outcom
patient
knowledg
first
literatur
combin
indic
innat
acquir
immun
predict
diseas
sever
outcom
detect
day
onset
peak
level
fourth
week
similar
antisarscovigg
respons
profil
previou
data
show
sever
sar
associ
robust
serolog
respons
includ
earli
seroconvers
day
higher
igg
level
low
antibodi
titr
observ
patient
mild
sar
diseas
viral
infect
consist
find
present
studi
support
robust
humor
respons
correl
diseas
sever
furthermor
believ
robust
acquir
antiigg
respons
contribut
viral
clearanc
also
lead
robust
immunemedi
tissu
damag
lymphopenia
neutrophilia
high
nlr
commonli
present
associ
sever
viral
infect
recent
data
indic
nlr
identifi
power
predict
prognost
factor
sever
thu
develop
simpl
combin
immun
respons
phenotyp
use
nlr
indic
innat
immun
igg
indic
acquir
immun
four
immun
respons
phenotyp
could
use
distinguish
sever
nonsever
case
predict
clinic
outcom
observ
sever
case
occur
nlr
hi
igg
hi
nlr
hi
igg
lo
phenotyp
three
dead
case
patient
nlr
hi
igg
hi
nlr
hi
igg
lo
appear
difficult
recov
sever
infect
compar
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
nlr
lo
igg
hi
nlr
lo
igg
lo
phenotyp
third
patient
nlr
lo
igg
hi
critic
ill
suggest
igg
respons
alon
could
lead
diseas
deterior
furthermor
high
cytokin
proinflammatori
cytokin
note
nlr
hi
igg
hi
nlr
hi
igg
lo
phenotyp
accordingli
specul
antiigg
humor
respons
directli
contribut
tissu
damag
sarscovmacaqu
model
liu
et
al
found
antispik
igg
presenc
high
antispik
igg
prior
viral
clearanc
abrog
woundheal
respons
promot
proinflammatori
cytokin
monocyt
chemotact
protein
product
monocytemacrophag
recruit
accumul
eventu
caus
fatal
acut
lung
injuri
sarscov
infect
thu
propos
potenti
mechan
associ
differ
immun
respons
phenotyp
present
specif
treatment
recommend
would
help
guid
clinic
decis
figur
exampl
nlr
hi
igg
lo
group
viru
directli
mediat
tissu
damag
cr
respons
diseas
develop
scenario
antiviru
tocilizumab
serum
convalesc
consid
howev
serum
convalesc
use
patient
low
igg
level
use
patient
high
igg
level
sinc
use
might
aggrav
diseas
especi
patient
nlr
hi
igg
hi
phenotyp
tocilizumab
treatment
might
benefici
patient
low
nlr
patient
immunosuppress
stage
rather
cr
stage
retrospect
investig
limit
firstli
viru
titer
monitor
infect
patient
recoveri
higher
igg
level
howev
previous
detect
patient
neg
predischarg
fecal
rtpcr
result
sarscovinfect
rhesu
macaqu
markedli
reduc
viru
titer
secondli
unknown
whether
chang
increas
igm
iga
relat
diseas
sever
mechan
respons
immunopatholog
reaction
igg
remain
elus
final
igg
respons
correl
sever
patient
without
highdos
corticosteroid
intervent
address
nevertheless
find
indic
sever
associ
robust
igg
respons
develop
acquir
immunityrel
marker
predict
diseas
sever
along
innat
immunityrel
maker
nlr
studi
immunopathogenesi
infect
warrant
jw
bz
qs
idea
design
studi
full
access
data
studi
take
respons
integr
data
accuraci
data
analysi
bizh
xz
cz
contribut
write
report
bz
contribut
critic
revis
report
jw
bizh
contribut
statist
analysi
author
contribut
data
acquisit
data
analysi
data
interpret
review
approv
final
version
author
declar
compet
interest
data
support
find
studi
avail
correspond
author
reason
request
particip
data
without
name
identifi
made
avail
approv
correspond
author
nation
health
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
commiss
public
studi
find
data
avail
other
request
research
team
provid
email
address
commun
data
approv
share
other
propos
detail
descript
studi
object
statist
analysi
plan
need
evalu
reason
request
data
correspond
author
make
decis
base
materi
addit
materi
may
also
requir
process
acknowledg
healthcar
worker
involv
diagnosi
treatment
patient
eastern
campu
renmin
hospit
wuhan
univers
thank
prof
hong
zhou
jiang
zheng
guidanc
manuscript
prepar
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
nonsever
patient
low
igm
level
auml
high
igm
level
auml
e
compar
frequenc
sever
nonsever
patient
low
igg
level
auml
high
igg
level
auml
clia
chemiluminesc
analysi
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
